The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from Business Wire

Exelixis Announces Webcasts of Upcoming Investor Conference Presentations

Thursday, August 30, 2012

Exelixis Announces Webcasts of Upcoming Investor Conference Presentations16:17 EDT Thursday, August 30, 2012 SOUTH SAN FRANCISCO, Calif. (Business Wire) -- Exelixis, Inc. (NASDAQ: EXEL) announced today that Michael M. Morrissey, Ph.D., the company's president and chief executive officer, will present at three upcoming investor conferences. Stifel Nicolaus 2012 Healthcare Conference: Exelixis' presentation will take place at 8:35 a.m. EDT / 5:35 a.m. PDT on Thursday, September 6, 2012, in Boston. BioCentury Newsmakers in the Biotech Industry 2012 Conference: Exelixis' presentation will take place at 10:30 a.m. EDT / 7:30 a.m. PDT on Friday, September 7, 2012, in New York. Morgan Stanley Global Healthcare Conference: Exelixis' presentation will take place at 8:35 a.m. EDT / 5:35 a.m. PDT on Tuesday, September 11, 2012, in New York. During each presentation, Dr. Morrissey will discuss the company's development program and plans for cabozantinib, and review the most recent publicly available data for the compound. He will also provide a general business update. Each presentation will be webcast and may be accessed via the Event Calendar page under Investors at www.exelixis.com. About Exelixis Exelixis, Inc. is a biotechnology company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its proprietary resources and development efforts exclusively on cabozantinib (formerly known as XL184), its most advanced product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis believes cabozantinib has the potential to be a high-quality, broadly-active, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs, many of which are being advanced by partners as part of collaborations. For more information, please visit the company's web site at www.exelixis.com. Exelixis, Inc.Charles Butler, 650-837-7277Vice President, Investor Relations and Corporate Communicationscbutler@exelixis.com